Healthcare / BiotechnologyNasdaqGS
$3.34
-0.12 (-3.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-165.8M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$513M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-586.6%
↓Gross Margin
N/A
•Debt/Equity
0.66
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-409.3%
FCF / Net income
1.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $40.5M · net income $-160.1M · FCF $-165.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | $40.5M | $40.5M | $32.3M | $78.1M | $19.7M | $25.5M | $90.7M | $20.5M | $31.9M | $13.7M | $6.1M | — | — |
| Net Income | $-160.1M | $-160.1M | $-237.1M | $-153.2M | $-220.4M | $-192.5M | $-116.0M | $-133.7M | $-110.0M | $-120.3M | $-97.2M | $-72.9M | $-13.7M |
| EBITDA | $-148.6M | $-148.6M | $-229.1M | $-163.1M | $-219.6M | — | — | — | — | — | — | — | — |
| EPS | — | — | -2.88 | -2.02 | -3.21 | -2.85 | -1.98 | -2.68 | — | — | — | — | — |
| Operating Margin | -245.2% | -245.2% | -739.4% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | -873.6% | -1605.6% | — | — |
| Net Margin | -395.0% | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | -876.5% | -1605.5% | — | — |
| Balance Sheet | |||||||||||||
| Debt/Equity | 0.66 | 0.66 | 0.26 | 0.10 | 0.12 | — | — | — | — | — | — | — | — |
| Current Ratio | 3.22 | 3.22 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-165.8M | $-165.8M | $-219.1M | $-136.9M | $-181.5M | $-171.8M | $-187.0M | $-46.8M | $-50.5M | $-11.5M | $-53.7M | $-6.9M | — |
| Returns | |||||||||||||
| ROE | -586.6% | -586.6% | -176.6% | -43.9% | -61.1% | -34.8% | -29.5% | -51.0% | -46.6% | -57.8% | -72.2% | 87.7% | 89.5% |
| Valuation | |||||||||||||
| P/B | 11.98 | 11.98 | 0.82 | 1.98 | 1.71 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| Revenue Growth | 25.4% | 25.4% | -58.6% | 296.3% | — | -71.8% | 341.9% | -35.7% | 132.6% | 126.8% | — | — | — |
| EPS Growth | — | — | -42.6% | 37.1% | — | -43.9% | 26.1% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+94.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.88 → n/d
Residual
+94.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.